Bevacizumab biosimilar is under clinical development by Synermore Biologics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bevacizumab biosimilar overview

Bevacizumab biosimilar (SYN-050) is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic cervical cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The drug candidate is administered through intravenous route. It acts by targeting vascular endothelial growth factor A (VEGFA). It was also under development for the treatment of metastatic renal cell carcinoma.

Synermore Biologics overview

Synermore Biologics (Synermore) is a biotechnology company that researches and develops biosimilar monoclonal antibodies. It develops its products in the therapeutic areas of oncology, immune disorders and infectious diseases. Its pipeline products include SYN004, SYN008, SYN125, SYN050, SYN060, SYN112, SYN109 and others. Synermore has developed technologies and platforms necessary for the development and production of therapeutic monoclonal antibodies including preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, and antibody drug formulation. The company also operates though its office located in Suzhou, China. Synermore is headquartered in Taipei City, Taiwan.

For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.